drugset / Trial / NCT00140647
The Study of Atherosclerosis With Ramipril and Rosiglitazone
Phase 3
Completed
1200 enrolled
Gerstein, Hertzel, MD
Heart and Stroke Foundation of Ontario · collab
RandomizedFactorialDouble-blindPrevention
Summary
The purpose of this study is to determine if ramipril and/or rosiglitazone retard the progression of atherosclerosis as evaluated by serial carotid intermedial thickness measurements.
Timeline
- Start
- 2001-07
- Primary completion
- —
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramipril | Small molecule | 15 mg | — |
| Subject | Rosiglitazone | Small molecule | 8 mg | — |